68 results
8-K
EX-10.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
on representations made by Remainco, Spinco, Parent, and their respective representatives, and not by independent review, and shall function only as an expert
425
3fvx 23my2tc
24 Mar 22
Business combination disclosure
9:09am
8-K
EX-2.1
3etjzhrwu4h5rnoqzm1t
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-99.1
57mv0ci4 2mb
29 Jul 21
Ligand Reports Second Quarter 2021 Financial Results
4:04pm
8-K
EX-2.1
tzzb4n5pyys38w qti
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-10.4
uih5n8td
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm